Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels

EVAX
Evaxion A/S
stock NASDAQ ADR

At Close
Nov 7, 2025 3:59:30 PM EST
6.39USD+1.914%(+0.12)161,671
5.22Bid   7.30Ask   2.08Spread
Pre-market
Nov 7, 2025 8:13:30 AM EST
6.12USD-2.392%(-0.15)582
After-hours
Nov 6, 2025 4:26:30 PM EST
6.33USD+0.957%(+0.06)0
OverviewPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 26, 2022
07:42AM EST  Evaxion Biotech Announces Publication Of Clinical Data Of EVX-01 In OncoImmunology Journal   Benzinga
07:30AM EST  Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced today the publication of a paper on personalized therapy with EVX-01 in patients with metastatic melanoma in the open access, peer-reviewed journal OncoImmunology.   GlobeNewswire Inc
Jan 18, 2022
08:17AM EST  Evaxion Biotech Receives Australia Therapeutic Goods Administration Clearance To Initiate Phase 2 Trial Of EVX-01 In Combination With KEYTRUDA For Treatment Of Melanoma   Benzinga
08:00AM EST  Evaxion Biotech Receives Regulatory Clearance to Initiate Phase 2   GlobeNewswire Inc
Nov 9, 2021
11:42AM EST  The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data   Benzinga
11:28AM EST  Evaxion Biotech Q3 EPS $(0.27) Down From $(0.26) YoY   Benzinga
06:30AM EST  Evaxion Biotech Announces Q3 2021 Financial Results and Provides   GlobeNewswire Inc
Nov 5, 2021
02:57PM EDT  Mid-Afternoon Market Update: Dow Surges 200 Points; Grid Dynamics Shares Spike Higher   Benzinga
12:35PM EDT  Mid-Day Market Update: Gold Rises 1%; Deciphera Pharmaceuticals Shares Plummet   Benzinga
10:19AM EDT  Mid-Morning Market Update: Markets Open Higher; US Economy Adds 531,000 Jobs   Benzinga
09:36AM EDT  Evaxion Biotech Prices ~3.43M ADS Offering At $7/ADS   Benzinga
06:00AM EDT  Evaxion Biotech Announces Pricing of $24.0 Million Follow-on   GlobeNewswire Inc
Nov 4, 2021
10:59AM EDT  Mid-Morning Market Update: Markets Mixed; Moderna Lowers Covid-19 Vaccine Sales Outlook   Benzinga
Oct 26, 2021
07:50AM EDT  Evaxion Biotech Files F-1 For Proposed Follow-On Offering Of Common Stock, No Size Disclosed   Benzinga
07:49AM EDT  Evaxion Biotech Announces Filing of Registration Statement in the   GlobeNewswire Inc
Oct 25, 2021
06:09AM EDT  Evaxion Biotech Announces Clinical Collaboration With Merck To Evaluate Lead Product Candidate With KEYTRUDA (pembrolizumab) In Patients With Melanoma   Benzinga
05:52AM EDT  Evaxion Biotech A/S (EVAX) has entered into a clinical trial collaboration and supply agreement with subsidiaries of Merck & Co. to evaluate the combination of Evaxion's cancer immunotherapy EVX-01 with MSD's KEYTRUDA in a new phase 2b study. Evaxion will be responsible for the conduct of the study.   RTTNews
05:45AM EDT  Evaxion to collaborate with MSD on Phase 2b trial with EVX-01   RTTNews
05:30AM EDT  Evaxion Biotech Announces Clinical Collaboration to Evaluate Lead   GlobeNewswire Inc
Oct 14, 2021
07:30AM EDT  -- Recognizes achievements in AI-enabled drug discovery -- Highlights how Evaxions platforms help to design novel immunotherapies efficiently   GlobeNewswire Inc
Oct 12, 2021
04:05PM EDT  Evaxion Biotech to Present Work on AI-Immunology Core Technology   GlobeNewswire Inc
Sep 21, 2021
08:38AM EDT  Evaxion Biotech Appoints Dr. Birgitte Rn   Benzinga
08:35AM EDT  -- Dr. Rn has developed Evaxion's pre-clinical and early clinical oncology pipeline -- Newly-created Chief Scientific Officer role strengthens Evaxion's leadership team   GlobeNewswire Inc
Sep 2, 2021
07:03AM EDT  The following are some of the stocks making big moves in Thursday's pre-market trading (as of 6.45 A.M. EDT).   RTTNews
Sep 1, 2021
10:50AM EDT  Shares of Evaxion Biotech A/S (EVAX) are gaining over 16% on Wednesday morning despite no stock-related news to drive the shares.   RTTNews
Aug 12, 2021
08:09AM EDT  The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma   Benzinga
06:51AM EDT  Evaxion Biotech Q2 Net Loss $6.8 Mln Or $0.36/Shr Vs Loss $3.6 Mln Or $0.24/shr Last Year   RTTNews
06:34AM EDT  Evaxion Biotech Q2 EPS $(0.36) Down From $(0.24) YoY   Benzinga
06:30AM EDT  -- Data reported in early July from EVX-01 clinical program showed a robust anti-tumor effect in combination with anti-PD-1 treatment for patients with metastatic melanoma, supporting advancement into a Phase 2b clinical trial   GlobeNewswire Inc
Aug 9, 2021
11:07AM EDT  The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight   Benzinga
Jul 8, 2021
09:10AM EDT  Evaxion's Cancer Immunotherapy Shows Antitumor Effect In Early-Stage Melanoma Study   Benzinga
07:45AM EDT  The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test   Benzinga
06:06AM EDT  Evaxion Biotech Reports Results From Phase 1/2a Trials Of EVX-01 In Metastatic Melanoma And EVX-02 In Adjuvant Melanoma   RTTNews
06:02AM EDT  Evaxion Biotech Reports Data from Phase 1/2a Trials of EVX-01 and EVX-02   Benzinga
Jul 7, 2021
05:02PM EDT  Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer, bacterial diseases and viral infections, announced today that it will hold a conference call to discuss Phase 1/2a data on EVX-01 and EVX-02 on Thursday, July 8, 2021.   GlobeNewswire Inc
Jun 25, 2021
07:31AM EDT  Evaxion Biotech Reports Acceptance Of New Scientific Paper By Int'l. Conference On Machine Learning   Benzinga
07:30AM EDT  Evaxion Develops Method to Enhance AI Drug Development with Deep   GlobeNewswire Inc
Jun 3, 2021
08:27AM EDT  Evaxion Biotech A/S (EVAX) said preclinical data showed that the company's RAVEN platform and proprietary APC targeting DNA vaccine technology have the potential to make a significant contribution in addressing corona viruses.   RTTNews
07:46AM EDT  Evaxion Biotech Reports Preclinical Proof Of Concept Data For AI-powered Vaccine Platform RAVEN   RTTNews
07:33AM EDT  Evaxion Biotech Reports Preclinical Proof Of Concept Data For Evaxion's AI-powered Vaccine Platform RAVEN For The Design Of A Next Generation SARS-CoV-2 Vaccine   Benzinga
07:30AM EDT  Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotech company developing AI-driven immunotherapies and vaccines to improve the lives of patients with cancer and infectious diseases, announced today new preclinical data from its Adaptive and Intelligent Vaccine for a Rapid Response against Corona Viruses (AICoV) program.   GlobeNewswire Inc
May 26, 2021
08:37AM EDT  Evaxion Biotech Appoints Lars Holtug To Board   RTTNews
08:30AM EDT  Evaxion Biotech Appoints Lars Holtug to the Board of Directors   GlobeNewswire Inc
May 13, 2021
07:36AM EDT  Evaxion Biotech Q1 EPS $(0.23) Beats $(0.30) Estimate   Benzinga
07:30AM EDT  -- Raised net proceeds of $27.9 million in U.S. initial public offering in February 2021 -- Lead programs EVX-01 and EVX-02 on track for Phase 1/2a data readouts late in Q2 -- Product candidates EVX-03 and EVX-B1 progressing through pre-clinical development -- Cash reserves of $27 million at March 31, 2021   GlobeNewswire Inc
04:15AM EDT  Earnings Scheduled For May 13, 2021   Benzinga
May 6, 2021
07:30AM EDT  Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer, bacterial diseases and viral infections, announced today that it will present its first-quarter 2021 financial results on May 13.   GlobeNewswire Inc
Apr 20, 2021
07:37AM EDT  Evaxion Biotech Highlights Presentation Of Paper On Potential Of Deep Data On Immune Complex Stability To Optimize Cancer Immunotherapy   Benzinga
07:30AM EDT  Evaxion Biotech Presents Paper on Potential of Deep Data on Immune   GlobeNewswire Inc
Apr 6, 2021
07:35AM EDT  Evaxion Biotech FY20 EPS $(0.97), Down From $(0.81) YoY   Benzinga
07:30AM EDT  Evaxion Biotech Announces Q4 and Full-Year 2020 Financial Results   GlobeNewswire Inc
04:17AM EDT  Earnings Scheduled For April 6, 2021   Benzinga
Mar 31, 2021
07:41AM EDT  The Daily Biotech Pulse: Pfizer Vaccine 100% Effective In Adolescents, Equillium Readout, Amgen Goes Shopping, Achilles IPO   Benzinga
Mar 30, 2021
08:06AM EDT  The Daily Biotech Pulse: Wave Life Sciences Pulls Plug On 2 Assets, Amarin's Vascepa Snags European Approval, Biocept Jumps On Earnings   Benzinga
07:30AM EDT  Evaxion Biotech A/S (Nasdaq: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced today that it will present its full-year financial results for 2020 on April 6.   GlobeNewswire Inc
Mar 26, 2021
07:28AM EDT  The Daily Biotech Pulse: FDA Nod For Astellas, Seagen, Gilead Get Positive Regulatory Tidings From Europe, 3 IPOs   Benzinga
Mar 25, 2021
07:58AM EDT  The Daily Biotech Pulse: Bristol-Myers Squibb's Skin Cancer Readout, Cellect Strikes Reverse Merger Deal, Lava Therapeutics Makes Nasdaq Debut   Benzinga
Mar 16, 2021
07:30AM EDT  Evaxion Biotech Announces Publication of Study on S. aureus   GlobeNewswire Inc
Mar 2, 2021
11:08AM EST  Oppenheimer Initiates Coverage On Evaxion Biotech with Outperform Rating, Announces Price Target of $18   Benzinga
Feb 27, 2021
09:04PM EST  The Week Ahead In Biotech (Feb. 28-March 6): KemPharm, Gilead FDA Decisions and More Earnings   Benzinga
Feb 24, 2021
07:30AM EST  The Daily Biotech Pulse: Bausch Calls Truce With Icahn, Pfizer's Brain Inflammation Vaccine Gets Priority Review, BriaCell IPO   Benzinga
Feb 18, 2021
08:14AM EST  The Daily Biotech Pulse: Lily-Rigel Licensing Deal, vTv Starts Early Stage Psoriasis Study, Immunic Data Readout   Benzinga
Feb 17, 2021
07:27AM EST  The Daily Biotech Pulse: Novartis Funding For Gene Therapy Research, Priority Review For Amgen Cancer Drug, Pfizer-BioNTech Vaccine Supply Deal   Benzinga
Feb 16, 2021
07:46AM EST  Evaxion Biotech Says Opens New Office, Laboratories To 'Support Future Growth'   Benzinga
07:30AM EST  Evaxion Biotech A/S (Nasdaq: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced today the opening of its new corporate headquarters and research laboratory facility located in the DTU Science Park in Hoersholm near Copenhagen, Denmark.   GlobeNewswire Inc
Feb 10, 2021
07:30AM EST  Evaxion Biotech Closes its U.S. Initial Public Offering of   GlobeNewswire Inc
Feb 9, 2021
08:10AM EST  The Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues Negative Preannouncement   Benzinga
Feb 5, 2021
12:20PM EST  Evaxion Shares Open For Trade At $10; IPO Priced At $10/ADS   Benzinga
10:30AM EST  Evaxion Biotech Shares Will Open For Trade At 11:50 a.m. EST, Expected To Open For Trade After 12:00 p.m. EST; IPO Priced At $10/ADS   Benzinga


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-5
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC